Twist Bioscience Corp. reported fiscal 2026 second‑quarter revenue of $110.72 million, surpassing the consensus estimate of $107.83 million. The company posted an adjusted loss of $0.62 per share, wider than the consensus loss of $0.48, and a loss of $0.71 per share, which is also outside the range of analyst expectations. The revenue beat represents a 19% year‑over‑year increase, while the loss per share widened by roughly 30% compared with the $0.48 consensus.
DNA synthesis and protein solutions revenue rose 28% to $53.3 million, the largest contributor to the top‑line growth. NGS Applications revenue increased 12% to $57.4 million. Gross margin expanded to 51.6% from 49.6% in Q2 2025, driven by a shift toward higher‑margin silicon‑chip synthesis and improved operational leverage. The company’s total revenue of $110.72 million represents a 19% increase over the $92.8 million reported in Q2 2025 and a 6% rise over the $103.7 million recorded in Q1 2026.
Management raised its fiscal‑2026 revenue guidance to $442 million–$447 million, up from the prior range of $435 million–$440 million. The company reiterated its expectation of reaching adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 and maintaining gross margin above 52% for the year. The guidance increase signals confidence in sustained demand, particularly from AI‑enabled drug discovery customers, and reflects the company’s ability to scale its silicon‑chip platform.
CEO Emily M. Leproust said, "We had a strong performance in the first half of fiscal 2026, ending the second quarter with our thirteenth consecutive quarter of growth. Revenue exceeded guidance, coming in at $110.7 million, growth of over 19% compared to the second quarter of 2025." She added, "As we look ahead, we remain focused on delivering consistent, measurable growth designed to scale over time. We expect to chart toward profitability while simultaneously building on the strong momentum we are seeing across the portfolio. We continue to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while holding gross margin above 52% for the fiscal year." COO Patrick Finn highlighted operational gains, noting, "Production acceptance rates for clonal genes are now at approximately 98.5%, with future targets of 99.5% for clonal genes and 99.9% for all DNA products." The company also announced that Amazon Web Services had named Twist a wet‑lab partner for its Amazon BioDiscovery AI‑powered drug discovery platform, underscoring the company’s position in the AI‑driven life‑science market.
Twist disclosed a settlement in principle for a securities class action, with a total settlement amount of $17.1 million. The company booked $7.2 million in litigation settlement costs for the quarter, reflecting the ongoing legal exposure.
Investor sentiment was mixed, with analysts weighing the revenue beat against the wider EPS miss. The company’s guidance raise and margin expansion provided a positive backdrop, but the loss per share and the booked litigation costs tempered enthusiasm.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.